Surface Oncology to Present at the UBS Virtual Global Healthcare Conference

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Jeff Goater will present at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 10 a.m. EDT. The presentation will cover Surface's lead programs, SRF617 targeting CD39 and SRF388 targeting IL-27. Live audio and archived webcasts will be available on the company's investor relations website. Surface Oncology focuses on developing next-generation immunotherapies aimed at achieving sustained anti-tumor responses through innovative antibody therapies.

News Market Reaction – SURF

-2.28%

-2.28% Session move

In the trading session that priced this news, SURF declined 2.28%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its chief executive officer, Jeff Goater, will present at the upcoming UBS Virtual Global Healthcare Conference, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27).

The presentation will take place virtually on Wednesday, May 20, 2020 at 10 a.m. EDT. The live audio and subsequent archived webcasts of the Company’s presentations will be accessible from the Company’s investor relations website: investors.surfaceoncology.com.

About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R) or depleting regulatory T cells (via targeting CCR8). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698

Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397

 

FAQ

When will Surface Oncology present at the UBS Virtual Global Healthcare Conference?

Surface Oncology will present at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 10 a.m. EDT.

What are the lead programs Surface Oncology is discussing at the conference?

Surface Oncology is discussing its lead programs, SRF617 targeting CD39 and SRF388 targeting IL-27, at the conference.

Where can I find the live webcast of Surface Oncology's presentation?

The live audio and archived webcasts of Surface Oncology's presentation can be accessed on their investor relations website.

What is the focus of Surface Oncology's research?

Surface Oncology focuses on developing next-generation immunotherapies that target the tumor microenvironment for cancer treatment.

What are the goals of Surface Oncology's immunotherapy programs?

Surface Oncology's immunotherapy programs aim to achieve clinically meaningful and sustained anti-tumor responses.